The impact of ethambutol optic toxicity on treatment of MDR TB Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Efficacy of intravenous isoniazid, rifampin and ethambutol administration in patients with failed treatment of tuberculosis and malabsorption syndrome Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Rapid oral desensitisation to ethambutol, rifampicin and isoniazid Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009
The influence phenotype of hydroxylation on anti-tuberculosis drug-induced hepatotoxicity Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006
Ethambutol optic toxicity: the importance of color perception testing Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006
A case with rifampicin induced severe trombocytopenia during tuberculosis treatment Source: Annual Congress 2007 - Difficult tuberculosis cases I Year: 2007
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
In vitro susceptibility to rifampin and ethambutol and treatment outcome in MAC lung disease Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM) Year: 2018
Monitoring of amikacin-induced ototoxicity during the treatment of multidrug resistant tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB) Source: Annual Congress 2007 - Epidemiology of tuberculosis II Year: 2007
Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001
Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020